FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Recruiting · NCT06636682 · Registry updated 2024-10-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2024-10-21 | NCT06636682 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cellvax Therapeutics Inc | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Carolina Urologic Research Center | Myrtle Beach | United States | 55 |
| Central Ohio Urology Group | Gahanna | United States | 14 |
| University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic | Chicago | United States | 1 |